MAP2K7 and non-small cell lung carcinoma: Consequently, clinical trials were performed to evaluate combined therapy with osimertinib and a MEK inhibitor (NCT03392246) in advanced EGFR-mutant NSCLC, and another with a c-MET inhibitor (NCT03778229) in advanced NSCLC with EGFR-mutation or MET-amplification [60,61].